These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7873994)

  • 1. Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.
    Joshua DE; Brown RD; Gibson J
    Leuk Lymphoma; 1994 Nov; 15(5-6):375-81. PubMed ID: 7873994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in multiple myeloma.
    Kyle RA
    Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of the escape phase of myeloma.
    Joshua DE; Gibson J; Brown RD
    Blood Rev; 1994 Mar; 8(1):13-20. PubMed ID: 8205006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
    Gadó K; Domján G; Hegyesi H; Falus A
    Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
    Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
    Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors in multiple myeloma. Review of the literature].
    Bauduer F; Troussard X; Delmer A
    Bull Cancer; 1993 Dec; 80(12):1035-42. PubMed ID: 8081040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
    Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
    Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell myeloma--new biological insights and advances in therapy.
    Barlogie B; Epstein J; Selvanayagam P; Alexanian R
    Blood; 1989 Mar; 73(4):865-79. PubMed ID: 2465790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The wide variations of the clinical behavior and prognosis in multiple myeloma].
    Kanoh T; Hirashimizu K
    Rinsho Ketsueki; 1993 Apr; 34(4):439-43. PubMed ID: 8510330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
    Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
    Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
    Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
    Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why better prognostic factors for multiple myeloma are needed.
    Kyle RA
    Blood; 1994 Apr; 83(7):1713-6. PubMed ID: 8142638
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma. Mechanisms of proliferation and neoplastic progression and their clinical implications].
    Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A
    Haematologica; 1991 Jun; 76 Suppl 3():100-6. PubMed ID: 1752506
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP; Liautard J; Klein B; Brochier J
    Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.